Global Combination Products 2025: Regulatory Convergence, PMOA Strategy & Compliance Trends

Combination products integrating drugs, biologics, medical devices, software, and digital health technologies into unified therapeutic solutions are transforming the future of healthcare delivery. From drug-eluting stents, insulin pens, wearable injectors, connected inhalers, AI-enabled infusion systems, and companion digital therapeutics, combination products represent one of the fastest-growing sectors in global life sciences.

As healthcare moves toward precision medicine, connected care, patient-centric treatment models, and advanced therapeutic delivery, regulators worldwide are rapidly evolving their frameworks to address the increasing complexity of these hybrid products.

The global combination products market, valued at approximately USD 138.48 billion in 2023, is projected to exceed USD 251.9 billion by 2030, driven by increasing biologic therapies, smart medical technologies, and integrated drug-device innovation.

However, despite technological advancement, global regulatory harmonization remains incomplete. Manufacturers must navigate complex jurisdictional pathways, evolving classification rules, hybrid quality expectations, cybersecurity obligations, and divergent post-market requirements.

At Maven Regulatory Solutions, we support pharmaceutical, biotechnology, and medical device manufacturers with global combination product strategies, PMOA classification support, regulatory intelligence, submission planning, lifecycle management, and integrated compliance programs aligned with evolving international expectations.

Understanding Combination Products

Combination products combine two or more regulated components into a single therapeutic or diagnostic solution.

Combination Product Categories

Why Combination Products Are Growing Rapidly

Several industry trends are accelerating combination product development globally:

• Growth of biologics and advanced therapies 
• Rise of home healthcare and self-administration 
• Expansion of digital health ecosystems 
• Increased focus on patient adherence 
• Personalized Medicine Initiatives 
• AI-enabled therapeutic monitoring 
• Connected medical technologies 

These products improve:

• Drug delivery precision 
• Patient convenience 
• Treatment adherence 
• Clinical outcomes 
• Remote monitoring capabilities 

However, they also introduce significant regulatory complexity.

Global Regulatory Frameworks for Combination Products

1. United States (FDA)

In the United States, combination products are regulated under 21 CFR Part 4 with oversight coordinated by the Office of Combination Products (OCP).

Core FDA Framework Elements

• PMOA-based classification system 
• Hybrid GMP/QSR compliance expectations 
• Integrated review pathways 
• Coordinated center oversight (CDER, CBER, CDRH) 
• eSTAR electronic submission integration 
• Lifecycle management oversight 

FDA Led Centers Based on PMOA

The FDA increasingly expects manufacturers to implement:

• Integrated quality systems 
• Human factors engineering 
• Cybersecurity controls 
• Software lifecycle management 
• Post-market surveillance programs 

2. European Union (EU MDR / EMA)

In Europe, combination products are regulated through overlapping frameworks including:

• Regulation (EU) 2017/745 (EU MDR) 
• Directive 2001/83/EC 
• EMA biologics frameworks 
• ATMP guidance structures 

EU Regulatory Challenges

Manufacturers often face complexity involving:

• Borderline product classification 
• Ancillary medicinal substance determination 
• Notified Body coordination 
• Hybrid technical documentation 
• Software and AI classification ambiguity 
• 3D-printed and custom-manufactured products 

3. Emerging Markets & Global Harmonization

International Harmonization Initiatives

Global organizations actively supporting regulatory convergence include:

• IMDRF 
• ICH 
• WHO 
• ASEAN harmonization programs 
• APEC regulatory initiatives 

Key Harmonization Drivers

Although progress continues, true global harmonization remains partial due to regional legal and operational differences.

Understanding PMOA: The Core of Combination Product Strategy

What Is PMOA?

Primary Mode of Action (PMOA) determines which constituent part provides the product’s primary therapeutic effect.

PMOA drives:

• Regulatory classification 
• Lead reviewing authority 
• Submission pathway 
• Quality system expectations 
• Inspection scope 
• Post-market obligations 

PMOA Classification Examples

Why PMOA Is Strategically Critical

Incorrect PMOA determination can lead to:

• Submission delays 
• Regulatory disputes 
• Duplicate data requests 
• Reclassification risk 
• Unexpected clinical evidence requirements 
• Increased compliance burden 

Early PMOA alignment is therefore essential for successful global submissions.

Key Steps in Combination Product Regulatory Strategy

1. Determine PMOA Early

Manufacturers must evaluate:

• Mechanism of therapeutic action 
• Clinical function 
• Device contribution 
• Biologic interaction 
• Software dependency 

2. Engage Regulators Early

Important regulatory interactions may include:

• FDA Request for Designation (RFD) 
• Pre-submission meetings 
• EMA scientific advice 
• Notified Body consultations 

Early engagement reduces classification uncertainty.

3. Build Integrated Submission Strategies

Combination product submissions often require integration of:

• CTD/eCTD modules 
• Device technical documentation 
• Design control records 
• Human factors studies 
• Cybersecurity documentation 
• Software validation evidence 

Combination Product Submission Pathways

Hybrid GMP and Quality System Expectations

Combination products often require manufacturers to comply with multiple quality frameworks simultaneously.

Common Compliance Expectations

Regulators increasingly conduct hybrid inspections covering:

• GMP 
• QSR 
• Data integrity 
• Design controls 
• Cybersecurity governance 
• Supplier qualification 

Major Regulatory Challenges in 2025

1. Borderline Product Classification

Regulators continue facing challenges involving:

• AI-enabled systems 
• Software-driven therapeutics 
• Companion applications 
• Digital biomarkers 
• Connected delivery systems 

2. Cybersecurity & Software Oversight

Connected combination products now require:

• Secure-by-design architecture 
• SBOM management 
• Vulnerability disclosure programs 
• Patch management systems 
• Real-time monitoring capabilities 

3. Post-Market Lifecycle Complexity

Manufacturers must manage:

• Firmware updates 
• Device modifications 
• Drug formulation changes 
• Software lifecycle updates 
• AI model retraining risks 

Global Regulatory Convergence vs. Ongoing Complexity

Why Global Harmonization Remains Difficult

Several structural barriers continue limiting convergence:

• Different legal definitions 
• Region-specific risk tolerance 
• Technology is evolving faster than regulations 
• Divergent terminology standards 
• Varying agency expertise levels 
• Inconsistent implementation timelines 

A 2024 analysis of FDA, EMA, and NMPA databases reportedly showed less than 45% terminology alignment across combination product classifications.

Emerging Trends Shaping Combination Product Regulation

1. AI & Digital Health Integration

Regulators increasingly focus on:

• AI-enabled therapeutic systems 
• Adaptive algorithms 
• Software updates 
• Predictive analytics 
• Real-world evidence integration 

2. Structured Electronic Submissions

New submission frameworks include:

• FDA eSTAR 
• EMA structured data initiatives 
• Digital lifecycle management systems 

3. Advanced Therapy Combination Products

Emerging products combine:

• Cell therapy 
• Gene therapy 
• Delivery devices 
• Smart monitoring systems 

These require hybrid biologic-device oversight models.

Strategic Recommendations for Manufacturers

1. Building Strong Regulatory Intelligence Programs

Monitor:

• Global PMOA changes 
• Classification guidance updates 
• Cybersecurity expectations 
• Digital health regulations 
• Hybrid inspection trends 

2. Integrate Quality Systems Early

Organizations should align:

• GMP 
• ISO 13485 
• Software lifecycle controls 
• Cybersecurity governance 
• Risk management systems 

3. Develop Cross-Functional Teams

Successful programs require collaboration between:

• Regulatory affairs 
• Quality assurance 
• Engineering 
• Clinical teams 
• Software developers 
• Cybersecurity specialists 

4. Invest in Digital Submission Infrastructure

Future readiness requires:

• Metadata-based dossier systems 
• Structured lifecycle management 
• Digital traceability 
• Integrated post-market monitoring 

Why Regulatory Intelligence Is Critical

Combination product regulations continue evolving rapidly.

Strong intelligence systems help manufacturers:

• Anticipate policy changes 
• Avoid submission delays 
• Align global strategies 
• Reduce rework costs 
• Maintain compliance continuity 

How Maven Regulatory Solutions Supports Combination Product Compliance

Our Services Include

• PMOA assessment and strategy 
• FDA OCP interaction support 
• Combination product submission planning 
• Hybrid GMP/QSR compliance consulting 
• Technical documentation preparation 
• EU MDR and FDA alignment strategies 
• Cybersecurity compliance support 
• Post-market surveillance planning 
• Regulatory intelligence monitoring 
• Global market access consulting 

Our multidisciplinary teams support integrated compliance across pharmaceutical, biologic, medical device, and digital health domains.

Conclusion

Combination products are redefining the future of global healthcare through integrated therapies, digital innovation, and patient-centric technologies.

However, as scientific innovation accelerates, regulatory complexity continues increasing across:

• PMOA classification 
• Hybrid quality systems 
• Cybersecurity governance 
• Digital lifecycle management 
• Post-market surveillance 
• Global submission harmonization 

While international agencies are moving toward greater regulatory convergence, manufacturers must still navigate fragmented frameworks, evolving guidance, and region-specific compliance expectations.

Organizations that implement proactive, intelligence-driven, cross-functional regulatory strategies will be best positioned to:

• Accelerate market access 
• Reduce compliance risk 
• Improve lifecycle management 
• Maintain global regulatory alignment 
• Support long-term innovation success 

At Maven Regulatory Solutions, we help life sciences companies navigate the evolving global combination product landscape through science-based strategy, regulatory expertise, and integrated compliance solutions designed for 2025 and beyond.

Frequently Asked Questions

1. What is a combination product?

A combination product combines drugs, biologics, devices, software, or other regulated components into a single therapeutic or diagnostic product.

2. What does PMOA mean?

PMOA stands for Primary Mode of Action, which determines the lead regulatory authority and submission pathway for a combination product.

3. Which FDA center regulates combination products?

Depending on PMOA, oversight may be assigned to CDER, CBER, or CDRH under the FDA Office of Combination Products.

4. Why are combination products difficult to regulate?

They involve overlapping requirements across pharmaceuticals, biologics, medical devices, software, cybersecurity, and post-market compliance frameworks.

5. What are the biggest regulatory trends?

Major trends include AI-enabled products, hybrid inspections, structured electronic submissions, cybersecurity oversight, and advanced therapy combinations.